E. David Crawford on the Side Effects of Treatments for Prostate Cancer

A Look Back at 2022 FDA Approvals in Oncology

Atezolizumab Plus Cabozantinib Meets PFS End Point in Phase 3 CONTACT-02 Trial in Hormone Therapy–Pretreated mCRPC

Key Advances in Cancer Survivorship Toxicity Management

FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

Bladder-Sparing Radiotherapy Yields Comparable Survival Outcomes to Radical Cystectomy in Nonmetastatic Node-Positive Bladder Cancer

FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC

A Look Back at 2022 FDA Approvals in Oncology

Atezolizumab Plus Cabozantinib Meets PFS End Point in Phase 3 CONTACT-02 Trial in Hormone Therapy–Pretreated mCRPC

Key Advances in Cancer Survivorship Toxicity Management

FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

Bladder-Sparing Radiotherapy Yields Comparable Survival Outcomes to Radical Cystectomy in Nonmetastatic Node-Positive Bladder Cancer

FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC

A Look Back at 2022 FDA Approvals in Oncology

Atezolizumab Plus Cabozantinib Meets PFS End Point in Phase 3 CONTACT-02 Trial in Hormone Therapy–Pretreated mCRPC

Key Advances in Cancer Survivorship Toxicity Management

FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

Bladder-Sparing Radiotherapy Yields Comparable Survival Outcomes to Radical Cystectomy in Nonmetastatic Node-Positive Bladder Cancer

FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC

Related Content

A Look Back at 2022 FDA Approvals in Oncology

The FDA has granted belzutifan priority review designation based on data from the phase 3 LITESPARK-005 trial.

Atezolizumab Plus Cabozantinib Meets PFS End Point in Phase 3 CONTACT-02 Trial in Hormone Therapy–Pretreated mCRPC

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Key Advances in Cancer Survivorship Toxicity Management

Cabozantinib and atezolizumab led to a statistically significant progression-free survival improvement in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease.

FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

Podcast

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Bladder-Sparing Radiotherapy Yields Comparable Survival Outcomes to Radical Cystectomy in Nonmetastatic Node-Positive Bladder Cancer

FoundationOne CDx is a next-generation sequencing–based in vitro diagnostic device developed to detect substitutions, insertion, and deletion alterations using 1 tissue sample.